普罗派坦卓 | 3638-82-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 普罗派坦卓
• 中文别名: 普罗雄醇
• 英文名称: Propetandrol
• 英文别名: [(3S,8R,9S,10R,13S,14S,17S)-17-ethyl-17-hydroxy-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] propanoate
• CAS: 3638-82-2
• 化学式: C₂₃H₃₆O₃
• 分子量: 360.5
• InChiKey: ODOMHABFTBNARE-JSDYAUHVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• Ceramic structures for prevention of drug diversion
  申请人：Moerck E. Rudi

  公开号：US20060127486A1

  公开（公告）日：2006-06-15

  The present invention is directed to compositions that provide drug delivery while resisting methods of diversion. The compositions are combinations of the drug and a ceramic structure. Any suitable drug may be used, but the drug is typically an opioid agonist. The ceramic structures arc usually metal oxides, and are oftentimes roughly spherical in shape with a hollow center.

  本发明针对的是既能提供药物输送又能抵御转移方法的组合物。这些组合物是药物和陶瓷结构的组合。可以使用任何合适的药物，但药物通常是阿片激动剂。陶瓷结构通常为弧形金属氧化物，通常呈大致球形，中心中空。
• EP1768651A4
  申请人：——

  公开号：EP1768651A4

  公开（公告）日：2008-09-10
• CERAMIC STRUCTURES FOR PREVENTION OF DRUG DIVERSION
  申请人：Altairnano, Inc

  公开号：EP1768651A2

  公开（公告）日：2007-04-04